FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition containing modafinil as the specified particles size. At least 95% of total content of modafinil particles have diameter less 200 micron. Indicated particles have the range of median diameter from 2 mcm to 60 mcm. Composition has from 50 mg to 700 mg of indicated modafinil. Specified size of modafinil particles provides the enhanced effectiveness of drug effect in treatment of patients sickness states associated with sleep disorders, Parkinson's disease, enuresis or Alzheimer's disease. EFFECT: enhanced effectiveness of composition. 10 cl, 9 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF MODAPHINYL AND METHOD FOR OBTAINING A PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2287987C2 |
| APPLICATION OF FLECAINIDE AS ANTICONNEXIN AGENT AND METHOD OF POTENTIATION OF EFFECTS OF PSYCHOTROPIC MEDICINES | 2014 |
|
RU2661026C2 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| USE OF AN INVERSE AGONIST H3R FOR TREATING SLEEP DISORDER IN SHIFT WORK | 2018 |
|
RU2768894C2 |
| NEW METHODS | 2014 |
|
RU2682658C1 |
| PHENYLEPHRINE RESINATE PARTICLES | 2014 |
|
RU2675788C2 |
| PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | 2014 |
|
RU2672731C2 |
| CONDENSED PYRROLO[2,3-C]CARBAZOL-6-ONES THAT ENHANCE ACTIVITY OF GAMMA-INTERFERON | 1997 |
|
RU2193037C2 |
| COMPOSITIONS AND METHODS FOR TREATING INSOMNIA | 2015 |
|
RU2703297C2 |
| APPLICATION OF K-252A DERIVATIVES TO TREAT DISORDERS OF PERIPHERAL OR CENTRAL NERVOUS SYSTEMS AND EXCESSIVE CYTOKINE OUTPUT | 1997 |
|
RU2183959C2 |
